Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer (VOXEL)

This study has been terminated.
(Recruitment rate to low; changed environment made protocol in its current state obsolete)
Sponsor:
Collaborator:
iOMEDICO AG
Information provided by (Responsible Party):
AIO-Studien-gGmbH
ClinicalTrials.gov Identifier:
NCT00950820
First received: July 31, 2009
Last updated: March 1, 2013
Last verified: March 2013

July 31, 2009
March 1, 2013
September 2009
November 2011   (final data collection date for primary outcome measure)
Progression-free survival rate at 6 months for subjects with KRAS wild-type tumours [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00950820 on ClinicalTrials.gov Archive Site
  • PFS [ Time Frame: end of study ] [ Designated as safety issue: No ]
  • Objective-response-rate [ Time Frame: end of study ] [ Designated as safety issue: No ]
  • Disease-control-rate [ Time Frame: end of study ] [ Designated as safety issue: No ]
  • Time-to-response [ Time Frame: end of study ] [ Designated as safety issue: No ]
  • time-to-progression [ Time Frame: end of study ] [ Designated as safety issue: No ]
  • duration-of-stable-disease [ Time Frame: end of study ] [ Designated as safety issue: No ]
  • time-to-treatment-failure [ Time Frame: end of study ] [ Designated as safety issue: No ]
  • overall-survival [ Time Frame: end of study ] [ Designated as safety issue: No ]
  • safety-endpoints [ Time Frame: end of study ] [ Designated as safety issue: Yes ]
PFS over the entire trial (XELOX+Panitumumab); PFS over the entire trial (XELOX only); ORR (entire treatment period); DCR; DOR; TTR; TTP; DoSD; Time to treatment failure; OS; Safety endpoints [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer
An Open-label Randomized Phase II Study of Panitumumab Plus Oral Capecitabine and Infusional Oxaliplatin (XELOX) or XELOX Alone for Second-line Treatment of Patients With Metastatic Colorectal Cancer (VOXEL-Study)

The purpose of this interventional study is to investigate whether there is evidence that panitumumab in combination with XELOX (capecitabine plus oxaliplatin) chemotherapy will safely increase progression-free survival, above that of XELOX alone in subjects with KRAS wild-type metastatic colorectal cancer who have not responded to or progressed after first line therapy with irinotecan and a fluoropyrimidine.

Further Objectives Exploratory objectives may include investigation of potential correlations between the treatment regimen and epidermal growth factor receptor (EGFR) expression, detection of the functional genetic polymorphisms of the EGFR gene, EGFR gene amplification (FISH), EGFR downstream protein and gene expression parameters, proteomics and epigenetics.

Subjects with metastatic colorectal cancer with KRAS-wildtype will be randomized in a 1:1 ratio to receive a 2nd line treatment regimen of panitumumab plus oxaliplatin and capecitabine (XELOX) or XELOX alone. Before randomization tumour of all subjects will be analyzed to detect the KRAS mutational status. Subjects will only be randomized into these two arms if the tumour shows KRAS wild-type. Subjects with KRAS mutant colorectal tumours will receive XELOX alone. Subjects will receive treatment cycles every three weeks. Treatment will continue until subjects are diagnosed with disease progression or intolerable toxicity, at which time the subjects will be withdrawn from the treatment phase. If a subject withdraws from chemotherapy due to toxicity the subjects will be allowed to continue with panitumumab monotherapy with or without one of the chemotherapy components until disease progression. After withdrawing panitumumab and XELOX treatment, all subjects will end the treatment phase and will enter a follow-up phase until 6 months after the last patient stopped treatment (with a safety follow-up visit after 56 days ± 3 days and long term follow-up visits every 12 weeks). During the treatment phase subjects will be evaluated for tumour response every 9 weeks (± one week) through to week 45, and every 12 weeks (± two weeks) thereafter, until disease progression. Subjects with symptoms suggestive of disease progression should be evaluated for tumour response at the time symptoms occur.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Colorectal Neoplasms
  • Drug: Oxaliplatin, Capecitabine, Panitumumab

    Panitumumab at a dose of 9 mg/kg BW every three weeks will be administered on day 1 of each cycle just prior to administration of chemotherapy.

    The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.

  • Drug: Oxaliplatin, Capecitabine
    The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.
  • Experimental: Panitumumab + XELOX
    KRAS mutational status wild-type: Panitumumab plus Oxaliplatin and Capecitabine (XELOX)
    Intervention: Drug: Oxaliplatin, Capecitabine, Panitumumab
  • XELOX (KRAS mutational status wt)
    KRAS mutational status wild-type: Oxaliplatin and Capecitabine (XELOX)
    Intervention: Drug: Oxaliplatin, Capecitabine
  • XELOX (KRAS mutational status mutant)
    KRAS mutational status mutant: Oxaliplatin and Capecitabine (XELOX)
    Intervention: Drug: Oxaliplatin, Capecitabine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
9
March 2012
November 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female patients aged 18 years or more, with histologically or cytologically-confirmed and radiologically-measurable metastatic colorectal cancer.
  • One prior chemotherapy regimen for mCRC consisting of first-line fluoropyrimidine and irinotecan based chemotherapy. Subjects must have disease progression (as assessed by the investigator) and must be no candidates for primary metastasectomy.
  • Measurable disease according to RECIST 1.1 guidelines. All sites of disease must have been evaluated within 28 days prior to registration / randomization, and diagnosed by the investigator.
  • Liver and kidney function within defined ranges and sufficient bone marrow reserve.

Exclusion Criteria:

  • Central nervous system metastases, or significant cardiovascular disease.
  • Prior anti-EGFR antibody therapy (e.g. cetuximab) or treatment with small molecule EGFR tyrosine kinase inhibitors (e.g. erlotinib).
  • Prior treatment with oxaliplatin for metastatic disease. Adjuvant therapy with oxaliplatin based combination for non-metastatic disease is allowed if terminated > 6 months prior to initiation of screening and without progression during the treatment with oxaliplatin.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00950820
AIO KRK 0107
Yes
AIO-Studien-gGmbH
AIO-Studien-gGmbH
iOMEDICO AG
Principal Investigator: Ralf Grunewald, PD Dr. Gemeinschaftspraxis Hämatologie / Onkologie Im Prüfling 17-19 60389 Frankfurt
AIO-Studien-gGmbH
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP